Mometasonfuroaat Sandoz (Mometasone Furoate)

Mometasone furoate acts as an agonist at glucocorticoid receptors in nasal mucosal cells. By binding these receptors, it alters gene transcription, suppressing inflammatory cytokine production, decreasing vascular permeability, and reducing mucosal edema, which collectively alleviate nasal inflammation.

The dose of Mometasonfuroaat Sandoz is determined by the prescribing healthcare professional based on the patient’s condition, age, and response to therapy. The prescriber will specify the number of sprays per nostril and the treatment duration.

Safety data for mometasone furoate nasal spray in pregnancy and lactation are limited. It should be used only if the potential benefit justifies any potential risk to the fetus or infant, and the decision should be made by the prescriber in consultation with the patient.

To order, submit an enquiry on the product page at gnhindia.com, indicating the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Mometasone furoate is a high‑potency intranasal corticosteroid with a low systemic bioavailability, offering effective symptom control with a favorable safety profile. Compared with older agents such as beclomethasone, it often requires fewer daily sprays while providing comparable or superior anti‑inflammatory effects.

Store the nasal spray at room temperature, below 25 °C, in its original packaging. Protect it from moisture and direct heat. Keep the device upright and avoid freezing. Do not share the spray with others.

The spray is administered intranasally. The patient should gently blow the nose, tilt the head slightly forward, insert the nozzle into one nostril, and press the actuator while breathing in gently through the nose. The prescribed number of sprays is repeated in the other nostril if indicated.

Serious risks include nasal septal perforation, severe or persistent nosebleeds, adrenal suppression with prolonged high‑dose use, and rare hypersensitivity reactions such as angioedema or anaphylaxis. Patients should seek medical attention if they experience any of these events.

Individuals with a known hypersensitivity to mometasone furoate or any component of the formulation should avoid the product. It is also contraindicated in patients with untreated nasal infections, recent nasal surgery or trauma, and those for whom systemic corticosteroid exposure is contraindicated.